Analyst Price Targets — MED
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 19, 2026 12:13 pm | — | Stephens | $12.00 | $10.71 | TheFly | Medifast price target lowered to $12 from $15 at Stephens |
| November 5, 2024 12:41 pm | Linda Bolton Weiser | D.A. Davidson | $17.00 | $20.40 | StreetInsider | DA Davidson Upgrades Medifast (MED) to Neutral |
| June 5, 2024 6:07 am | Linda Bolton Weiser | D.A. Davidson | $17.50 | $23.97 | StreetInsider | DA Davidson Downgrades Medifast (MED) to Underperform |
| April 30, 2024 5:00 am | Linda Bolton Weiser | D.A. Davidson | $25.00 | $35.51 | StreetInsider | Medifast (MED) PT Lowered to $25 at DA Davidson |
| June 5, 2023 9:09 am | Stephanie Wissink | Jefferies | $150.00 | $81.22 | Benzinga | Wall Street's Most Accurate Analysts Say Hold These 3 Defensive Stocks With Over 6% Dividend Yields |
| April 6, 2023 8:52 am | Linda Bolton Weiser | D.A. Davidson | $94.00 | $96.39 | Benzinga | Check Out 3 High-Yielding Dividend Stocks In Defensive Sector From Wall Street's Most Accurate Analysts |
Latest News for MED
BALTIMORE--(BUSINESS WIRE)--Medifast, Inc. (NYSE: MED) today announced the launch of Trilivy, a comprehensive metabolic health system uniquely designed to support healthy lifestyle change. The launch also introduces newly formulated meal replacements, including the Trilivy Reset Fueling line enhanced with MetaVantage Technology™, a platform of proprietary ingredient formulas intended to optimize metabolism by…
The heavy selling pressure might have exhausted for Medifast (MED) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
The weight loss and weight management market was valued at $31.07 billion in 2025 A program can describe its results as clinically meaningful without specifying what was measured, how it was measured, or whether the measurement tool was capable of capturing the outcome being claimed DXA scanning distinguishes fat mass, lean mass, and bone mineral content with greater precision than BMI calculations and just weight…
OPTAVIA's clinical program reduces visceral fat 14% and retains 98% lean mass, directly addressing the metabolic impact of perimenopause and menopause.
Medifast (MED) reported earnings 30 days ago. What's next for the stock?
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MED.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.